Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.

Tanaka T, Higashi M, Kimura K, Wakao J, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T.

J Pediatr Surg. 2016 Dec;51(12):2074-2079. doi: 10.1016/j.jpedsurg.2016.09.043. Epub 2016 Sep 16.

PMID:
27686482
2.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.

PMID:
29184034
3.

In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma.

Takeuchi Y, Tanaka T, Higashi M, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T.

J Pediatr Surg. 2018 Dec;53(12):2454-2459. doi: 10.1016/j.jpedsurg.2018.08.026. Epub 2018 Sep 1.

PMID:
30266481
4.

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, Aoki T, Shimma N, Arisawa M, Sowa Y, Poulikakos PI, Rosen N, Aoki Y, Sakai T.

Cancer Res. 2013 Jul 1;73(13):4050-4060. doi: 10.1158/0008-5472.CAN-12-3937. Epub 2013 May 10.

5.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

6.
7.

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.

Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE.

BMC Cancer. 2016 Mar 1;16:172. doi: 10.1186/s12885-016-2199-z.

8.

A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.

Kumamoto T, Aoki Y, Sonoda T, Yamanishi M, Arakawa A, Sugiyama M, Shirakawa N, Ishimaru S, Saito Y, Maeshima A, Maeda M, Ogawa C.

Int J Hematol. 2019 Feb;109(2):228-232. doi: 10.1007/s12185-018-2553-9. Epub 2018 Oct 25.

PMID:
30361829
9.

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.

PLoS One. 2014 Nov 25;9(11):e113217. doi: 10.1371/journal.pone.0113217. eCollection 2014.

10.

Targeting of MEK in lung cancer therapeutics.

Heigener DF, Gandara DR, Reck M.

Lancet Respir Med. 2015 Apr;3(4):319-27. doi: 10.1016/S2213-2600(15)00026-0. Epub 2015 Mar 20. Review.

PMID:
25801412
11.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
12.
13.

MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.

Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, Morrell D, Chakravarti A, Williams TM.

Cell Cycle. 2015;14(23):3713-24. doi: 10.1080/15384101.2015.1104437.

14.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

PMID:
19258520
15.

Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.

Kurata K, Onoda N, Noda S, Kashiwagi S, Asano Y, Hirakawa K, Ohira M.

Int J Oncol. 2016 Dec;49(6):2303-2308. doi: 10.3892/ijo.2016.3723. Epub 2016 Oct 7.

PMID:
27748799
16.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

17.

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.

Cancer Lett. 2016 Mar 1;372(1):75-81. doi: 10.1016/j.canlet.2015.12.015. Epub 2015 Dec 23.

PMID:
26723875
18.

Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM.

Int J Cancer. 2013 Feb 1;132(3):E149-57. doi: 10.1002/ijc.27781. Epub 2012 Sep 28.

19.

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.

Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.

Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.

20.

Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.

Mert I, Chhina J, Allo G, Dai J, Seward S, Carey MS, Llaurado M, Giri S, Rattan R, Munkarah AR.

Gynecol Oncol. 2017 Aug;146(2):319-326. doi: 10.1016/j.ygyno.2017.05.019. Epub 2017 May 22.

PMID:
28545687

Supplemental Content

Support Center